# Reviva Pharmaceuticals Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Reviva Pharmaceuticals Holdings, Inc.). ## Overview Reviva Pharmaceuticals Holdings, Inc. is a U.S.-based late-stage pharmaceutical company focused on discovering, developing, and seeking to commercialize new medicines for central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline centers on two internally discovered drug candidates, brilaroxazine (RP5063) and RP1208, supported by a proprietary chemistry and chemical genomics platform and a patent portfolio spanning the U.S., Europe, and other countries. ## Products & services • Brilaroxazine (RP5063) drug candidate • RP1208 drug candidate • Clinical development of CNS, inflammatory, and cardiometabolic therapies • Proprietary chemical genomics discovery platform • Patent portfolio for compositions of matter and methods of use - **Lead drug candidate development** (60%) — Development of brilaroxazine (RP5063) and related clinical-stage programs. - **Second pipeline asset** (20%) — Development of RP1208 and related preclinical or clinical work. - **Discovery platform** (10%) — Chemical genomics and proprietary chemistry used to identify new medicines. - **Intellectual property** (10%) — Patents and patent applications protecting compounds and methods of use. - Brilaroxazine (RP5063) drug candidate - RP1208 drug candidate - Clinical development of CNS, inflammatory, and cardiometabolic therapies - Proprietary chemical genomics discovery platform - Patent portfolio for compositions of matter and methods of use ## Customers Reviva does not sell to a broad commercial customer base today; its primary counterparties are regulators, clinical trial sites, investigators, and future pharmaceutical partners or licensees. The eventual end customers for its medicines would be patients and prescribing physicians in psychiatry, inflammatory disease, and cardiometabolic care. In the near term, the business is driven by clinical development and the ability to advance candidates through regulatory review. - **Regulators and approval authorities** (primary) — FDA and other agencies review trial data and determine whether candidates can advance or be approved. - **Clinical trial sites and investigators** (primary) — Hospitals, clinics, and investigators enroll patients and generate the safety/efficacy data needed for development. - **Pharmaceutical partners** (secondary) — Potential collaborators or licensees may support development, manufacturing, or commercialization. - **Future prescribers and patients** (emerging) — Psychiatrists and other specialists would use approved products if the pipeline reaches market. - Regulatory agencies evaluating clinical and approval packages - Clinical trial investigators and study sites running trials - Potential pharma partners or licensees for development/commercialization - Patients and physicians in CNS, inflammatory, and cardiometabolic care - Capital providers funding development before product sales exist ## Geography Reviva is headquartered in the United States and operates as a U.S.-listed development-stage pharmaceutical company. Its intellectual property footprint extends beyond the U.S. into Europe and more than 20 foreign countries, reflecting the global scope of patent protection for its pipeline. Clinical development and eventual commercialization would likely involve multiple jurisdictions, making regulatory and patent coverage geographically important. - Headquartered and listed in the United States - Clinical and regulatory work is centered on U.S. development pathways - Patent coverage extends across Europe and over 20 foreign countries - Future commercialization would depend on approvals in multiple jurisdictions - Global IP coverage helps protect pipeline value outside the U.S. ## Strategy Reviva’s strategy is to advance its two internally discovered drug candidates through late-stage clinical development and regulatory review, with brilaroxazine as the core program. The company also seeks to preserve and expand patent protection while securing the financing needed to complete trials and, if successful, prepare for commercialization or partnering. Its competitive position depends on generating differentiated clinical data in areas with significant unmet medical need. - **Complete late-stage clinical development of brilaroxazine** (short-term) — Clinical success is the main value driver for a development-stage pharmaceutical company. - **Maintain and expand intellectual property protection** (medium-term) — Patent exclusivity is essential to defend future commercial value and partnering leverage. - **Raise capital to fund development and operations** (short-term) — Clinical programs require ongoing funding before any product revenue can be generated. - Advance brilaroxazine through late-stage clinical development - Progress RP1208 as a second pipeline asset - Generate clinical data supporting safety, tolerability, and efficacy - Protect compounds with broad patent coverage - Secure financing to fund trials and commercialization readiness ## Risks Reviva faces the typical risks of a clinical-stage biotech company: trial failure, regulatory rejection, and the need for repeated external financing before commercialization. Its business is also exposed to execution risk in trial operations, third-party manufacturing, intellectual property protection, and going-concern uncertainty if capital is not raised on time. - **Clinical development failure** [critical] — Pipeline value depends on positive trial outcomes and successful progression through phases. - **Financing and going-concern risk** [critical] — The company has no commercial product revenue and relies on external capital to fund operations. - **Regulatory approval risk** [high] — FDA or other authorities may require additional data or reject applications. - **Manufacturing and supply chain dependence** [high] — Clinical and future commercial supply depends on third-party manufacturers and raw materials. - **Intellectual property protection** [high] — Patent scope and enforceability determine the duration of competitive exclusivity. - Clinical trials may fail to show efficacy or acceptable safety - Regulatory approval may be delayed or denied - Additional capital may not be available on acceptable terms - Third-party suppliers and manufacturers may underperform - Patent protection may be challenged or expire before value is realized ## Accounting The most important accounting issues for Reviva are clinical development expense recognition, fair value measurement of warrant liabilities, and stock-based compensation. Because the company is pre-revenue and development-stage, small changes in trial spending, financing structure, or valuation assumptions can materially affect reported losses and balance sheet presentation. - **Clinical trial expense recognition** — Affects R&D expense and quarterly loss volatility - **Fair value of warrant liabilities** — Can materially affect net income (loss) and volatility - **Stock-based compensation** — Increases operating expenses without immediate cash outflow - **Going-concern assessment** — Influences disclosure and investor assessment of financing risk - Clinical trial and development costs drive operating expense timing - Warrant liabilities are marked to fair value and can move earnings - Stock-based compensation affects non-cash expense and loss measures - Going-concern disclosures depend on cash runway and funding plans - Capital raises can change share count and dilution --- *Last updated: 2026-04-29T04:52:01.477477+00:00*